ARS Pharmaceuticals (SPRY) Return on Equity (2022 - 2025)
Historic Return on Equity for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 0.53%.
- ARS Pharmaceuticals' Return on Equity fell 2400.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 2400.0%. This contributed to the annual value of 0.03% for FY2024, which is 2500.0% up from last year.
- Per ARS Pharmaceuticals' latest filing, its Return on Equity stood at 0.53% for Q3 2025, which was down 2400.0% from 0.28% recorded in Q2 2025.
- Over the past 5 years, ARS Pharmaceuticals' Return on Equity peaked at 0.01% during Q4 2024, and registered a low of 0.53% during Q3 2025.
- In the last 4 years, ARS Pharmaceuticals' Return on Equity had a median value of 0.24% in 2023 and averaged 0.2%.
- As far as peak fluctuations go, ARS Pharmaceuticals' Return on Equity soared by 2800bps in 2024, and later tumbled by -2400bps in 2025.
- Quarter analysis of 4 years shows ARS Pharmaceuticals' Return on Equity stood at 0.13% in 2022, then plummeted by -119bps to 0.29% in 2023, then surged by 95bps to 0.01% in 2024, then plummeted by -3865bps to 0.53% in 2025.
- Its Return on Equity was 0.53% in Q3 2025, compared to 0.28% in Q2 2025 and 0.11% in Q1 2025.